VANCOUVER, Jan. 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leader
in the development of targeted therapeutic proteins, today announced that the
Company has received Institutional Review Board (IRB) approvals to proceed
with its Phase 2a clinical trial evaluating PRX302 for the treatment of
localized recurrent prostate cancer. Activities associated with patient
screening have commenced and the Company expects to enroll the first patient
in the first quarter of 2008.
